product name SC75741
References: Bioorg Med Chem Lett. 2007 Nov 1;17(21):5858-62; Cell Microbiol. 2013 Jul;15(7):1198-211.
565.67
Formula
C29H23N7O2S2
CAS No.
913822-46-5
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 35 mg/mL (61.9 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
other peoduct :
| In Vitro |
In vitro activity: SC75741 shows immunosuppressive activity by inhibiting human PBMC proliferation with IC50 of 2.2 μM. SC75741 inhibits replication of influenza A and B viruses by inhibiting NF-κB-mediated signalling on a transcriptional level. Moreover, SC75741 shows a high barrier for development of resistant virus variants. Kinase Assay: The NF-κB reporter gene assay is prepared with A549-NF-κB-SEAP cell line according to manufacturer’s instructions. In short, A549 cells stably transfected with pNF-κB-SEAP reporter gene plasmid are plated and allowed to attach overnight. The cells are subsequently incubated for 5 h with described compounds at 100, 30, 10, 3, 1, 0.3, 0.1, and 0 μM and then stimulated with 10 ng/ml TNF-α for 22 h. The supernatant of the cell is analyzed for SEAP activity using a chemiluminescent SEAP reporter gene assay. Cell Assay: Cell viability assay is prepared using a CellTiter-BluTM Cell Viability Assay. For each concentration of the compound four replicates are measured. |
|---|---|
| In Vivo | SC75741 (15 mg/kg i.p.) reduces virus replication and cytokine expression in mice lungs after H5N1 influenza virus infection. |
| Animal model | C57BL/6 mice infected with H5N1 influenza virus |
| Formulation & Dosage | Dissolved in 10% DMSO, 30% Cremophor EL and 60% PBS; 15 mg/kg; i.p. injection |
| References | Bioorg Med Chem Lett. 2007 Nov 1;17(21):5858-62; Cell Microbiol. 2013 Jul;15(7):1198-211. |
